|

Tiragolumab Clinical Trials

9 actively recruiting trials across 5 locations

Also known as: Anti-TIGIT, MTIG7192A, RG-6058, RO7092284, anti-TIGIT

Other3 trials

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Phase 3
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
Phase 2
Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients
Phase 2

Houston, Texas2 trials

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

M D Anderson Cancer Center

Phase 1/2
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

M D Anderson Cancer Center

Phase 2

Birmingham, Alabama1 trial

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

UAB Comprehensive Cancer Center

Phase 1

Costa Mesa, California1 trial

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

UC Irvine Medical Center

Phase 1/2

Duarte, California1 trial

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

City of Hope Comprehensive Cancer Center

Phase 1/2

San Francisco, California1 trial

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

University of San Francisco, California

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.